Psychopharmacology of Depression in Children and Adolescents

Pediatric Clinics of North America

Volumn 58, Issue 1, 2011, Pages 155-171

  Smiga, Susan M ^a   Elliott, Glen R ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Children's Health Council   (United States)

Author keywords

Adolescents; Children; Depressive disorders; Psychopharmacology

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; LITHIUM; MIRTAZAPINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ACNE; AGITATION; ANXIETY DISORDER; ATAXIA; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR MANIA; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COGNITIVE THERAPY; CONFUSION; DEPRESSION; DIABETES INSIPIDUS; DIAGNOSTIC ACCURACY; DISORIENTATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERSALIVATION; HYPOTHYROIDISM; INTERMETHOD COMPARISON; LEUKOCYTOSIS; LIPID BLOOD LEVEL; MAJOR DEPRESSION; MANIA; MUSCLE TWITCH; MYOCLONUS; PATIENT EDUCATION; PROFESSIONAL KNOWLEDGE; PROGNOSIS; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOLOGY; RECOMMENDED DRUG DOSE; REVIEW; SCREENING TEST; SEPSIS; SIDE EFFECT; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT PLANNING; TREMOR; WEIGHT GAIN;

ADOLESCENT; ADOLESCENT PSYCHIATRY; ANTIDEPRESSIVE AGENTS; CHILD; CHILD PSYCHIATRY; DECISION MAKING; DEPRESSION; HUMANS; PSYCHOPHARMACOLOGY;

EID: 79251564940     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.11.007     Document Type: Review

References (84)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders-3rd Edition revised 1987, American Psychiatric Association, Washington, DC. 3rd edition.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders-4th Edition 2000, American Psychiatric Association, Washington, DC. 4th edition.
3. Birmaher B., Arbelaez C., Brent D.A. Course and outcome of child and adolescent major depressive disorder. Child Adolesc Psychiatr Clin N Am 2002, 11:619-638.
4. Costello E.J., Pine D.S., Hammen C., et al. Development and natural history of mood disorders. Biol Psychiatry 2002, 52:529-542.
5. Hazell P. Depression in children and adolescents. Clin Evid 2004, 11:391-402.
6. Lagges A.M., Dunn D.W. Depression in children and adolescents. Neurol Clin 2003, 21:953-960.
7. Elliott G.R., Smiga S. Depression in the child and adolescent. Pediatr Clin North Am 2003, 50:1093-1106.
8. Costello E.J., Foley D.L., Angold A. 10-year research update review: the epidemiology of child and adolescent psychiatric disorders: I. Developmental epidemiology. J Am Acad Child Adolesc Psychiatry 2006, 45(1):8-25.
9. Kessler R.C., Avenevoli S., Ries Merikangas K. Mood disorders in children and adolescents: an epidemiologic perspective. Biol Psychiatry 2001, 49(12):1002-1014.
10. Besseghini V.H. Depression and suicide in children and adolescents. Ann N Y Acad Sci 1997, 816:94-98.
11. Compas B.E., Oppedisano G., Connor J.K., et al. Gender differences in depressive symptoms in adolescence: comparison of national samples of clinically referred and nonreferred youths. J Consult Clin Psychol 1997, 65:617-626.
12. Suris J.C., Parera N., Puig C. Chronic illness and emotional distress in adolescence. J Adolesc Health 1996, 19:153-156.
13. Stewart D.E. Physical symptoms of depression: unmet needs in special populations. J Clin Psychiatry 2003, 64(Suppl 7):12-16.
14. March J.S., Vitiello B. Advances in paediatric neuropsychopharmacology: an overview. Int J Neuropsychopharmacol 2001, 4:141-147.
15. Mann J.J., Oquendo M., Underwood M.D., et al. The neurobiology of suicide risk: a review for the clinician. J Clin Psychiatry 1999, 60(Suppl 2):7-11. [discussion: 18-20, 113-6].
16. Todd R., Botteron K.N. Etiology and genetics of early-onset mood disorders. Child Adolesc Psychiatr Clin N Am 2002, 11:499-518.
17. Bhangoo R.K. Affective neuroscience and the study of normal and abnormal emotion regulation. Child Adolesc Psychiatr Clin N Am 2002, 11:519-533.
18. Klein D.N., Lewinsohn P.M., Rohde P., et al. Psychopathology in the adolescent and young adult offspring of a community sample of mothers and fathers with major depression. Psychol Med 2005, 35:353-365.
19. Klein D.N., Shankman S.A., Lewinsohn P.M., et al. Family study of chronic depression in a community sample of young adults. Am J Psychiatry 2004, 161:646-653.
20. Williams S.B., O'Conor E.A., Eder M., et al. Screening for child and adolescent depression in primary care settings: a systematic evidence review for the US Preventive Services Task Force. Pediatrics 2009, 123:e716-e735.
21. Foy J.M., Kelleher K.J., Laraque D., American Academy of Pediatrics Task Force on Mental Health Enhancing pediatric mental health care: strategies for preparing a primary care practice. Pediatrics 2010, 125:S87-S108.
22. Committee on Psychosocial Aspects of Child and Family Health and Task Force on Mental Health Policy statement-the future of pediatrics: mental health competencies for pediatric primary care. Pediatrics 2009, 124:410-421.
23. Rohde P., Clarke G.N., Lewinsohn P.M., et al. Impact of comorbidity on a cognitive-behavioral group treatment for adolescent depression. J Am Acad Child Adolesc Psychiatry 2001, 40:795-802.
24. Angold A., Costello E.J., Erkanli A. Comorbidity. J Child Psychol Psychiatry 1999, 40:57-87.
25. Hughes C., Preskorn S.H., Weller E., et al. The effect of concomitant disorders in childhood depression on predicting treatment response. Psychopharmacol Bull 1990, 26:235-238.
26. Aseltine R.H., Gore S., Colten M.E. The co-occurrence of depression and substance abuse in late adolescence. Dev Psychopathol 1998, 10:549-570.
27. Lewinsohn P.M., Pettit J.W., Joiner T.E., et al. The symptomatic expression of major depressive disorder in adolescents and young adults. J Abnorm Psychol 2003, 112:244-252.
28. Strober M., Lampert C., Schmidt S., et al. The course of major depressive disorder in adolescents: I. Recovery and risk of manic switching in a follow-up of psychotic and nonpsychotic subtypes. J Am Acad Child Adolesc Psychiatry 1993, 32:34-42.
29. Kovacs M., Akiskal H.S., Gatsonis C, et al. Childhood-onset dysthymic disorder. Clinical features and prospective naturalistic outcome. Arch Gen Psychiatry 1994, 51:365-374.
30. Cheung A.H., Zuckerbrot R.A., Jensen P.S., et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management. Pediatrics 2007, 120(5):e1313-e1326.
31. Olfson M., Gameroff M.J., Marcus S.C., et al. Outpatient treatment of child and adolescent depression in the United States. Arch Gen Psychiatry 2003, 60:1236-1242.
32. Emslie G.J., Mayes T.L., Laptook R.S., et al. Predictors of response to treatment in children and adolescents with mood disorders. Psychiatr Clin North Am 2003, 26:435-456.
33. Birhamer B., Brent D., AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007, 46(11):1503-1526.
34. Hughes C.W., Emslie G.J., Crimson M.L., et al. Texas Children's Medication Algorithm project: update from Texas Consensus Conference Panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 2007, 46(6):667-686.
35. Zuckerbrot R.A., Cheung A.H., Jensen P.A., et al. Guidelines for Depression in Primary Care (GLAD-PC) I. Identification, assessment, and initial management. Pediatrics 2007, 120(5):e1299-e1312.
36. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 1998, 37(Suppl 10):63S-83S.
37. Emslie G.J., Hughes C.W., Crismon M.L., et al. A feasibility study of the childhood depression medication algorithm: the Texas Children's Medication Algorithm Project (CMAP). J Am Acad Child Adolesc Psychiatry 2004, 43:519-527.
38. March J., Silva S., Petrycki S., et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004, 292:807-820.
39. Brent D., Emslie G., Clarke G., et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008, 299(8):901-913.
40. Cheung A., Emslie G.J., Mayes T.L. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 2005, 46(7):735-754.
41. Ritvo R.Z., Papilsky S.B. Effectiveness of psychotherapy. Curr Opin Pediatr 1999, 11:323-327.
42. Compton S.N., March J.S., Brent D., et al. Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: an evidence-based medicine review. J Am Acad Child Adolesc Psychiatry 2004, 43:930-959.
43. Weisz J.R., Hawley K.M., Doss A.J. Empirically tested psychotherapies for youth internalizing and externalizing problems and disorders. Child Adolesc Psychiatr Clin N Am 2004, 13:729-815.
44. Brent D.A., Kolko D.J., Birmaher B., et al. Predictors of treatment efficacy in clinical trial of three psychosocial treatments for adolescent depression. J Am Acad Child Adolesc Psychiatry 1998, 37:906-914.
45. Birmaher B., Brent D.A., Kolko D., et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry 2000, 57:29-36.
46. Mufson L., Weissman M.M., Moreau D., et al. Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 1999, 56:573-579.
47. Gould M.S., Greenberg T., Velting D.M., et al. Youth suicide risk and preventive interventions: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 2003, 42:386-405.
48. Weiss J.R., McCarty C.A., Valeri S.M. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol Bull 2006, 132(1):132-149.
49. Hazell P., O'Connell D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2000, 3. CD002317.
50. Klein R.G., Mannuzza S., Koplewicz H.S., et al. Adolescent depression: controlled desipramine treatment and atypical features. Depress Anxiety 1998, 7:15-31.
51. Delate T., Gelenberg A.J., Simmons V.A., et al. Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatr Serv 2004, 55:387-391.
52. Emslie G.J., Rush A.J., Weinberg W.A., et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997, 54:1031-1037.
53. Emslie G.J., Rush A.J., Weinberg W.A., et al. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depress Anxiety 1998, 7:32-39.
54. Kastelic E.A., Labellarte M.J., Riddle M.A. Selective serotonin reuptake inhibitors for children and adolescents. Curr Psychiatry Rep 2000, 2:117-123.
55. Baumgartner J.L., Emilie G.J., Crimson M.L. Citalopram in children and adolescents with depression or anxiety. Ann Pharmacother 2002, 11:1692-1697.
56. Vaswani M., Linda F.K., Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:85-102.
57. Ryan N.D. Medication treatment for depression in children and adolescents. CNS Spectr 2003, 8:283-287.
58. Wagner K.D., Jonas J., Findling R.L., et al. A double-blind, randomized, placebo-controlled trial with escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006, 45(3):280-288.
59. Wagner K.D., Robb A.S., Findling R.I., et al. A randomized, placebo controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004, 161(6):1079-1083.
60. Emslie G.J., Croarkin P., Mayes T.L. Antidepressants. Dulcan's Textbook of Child and Adolescent Psychiatry 2009, 701-724. American Psychiatric Publishing, Washington, DC. M.K. Dulcan (Ed.).
61. Jick H., Kaye J.A., Jick S.S. Antidepressants and the risk of suicidal behaviors. JAMA 2004, 292:338-343.
62. Whittington C.J., Kendall T., Fonagy P., et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004, 363:1341-1345.
63. Bridge J.A., Iyengar S., Salary C.B., et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007, 297(15):1683-1696.
64. Wong I.C., Besag F.M., Santosh P.J., et al. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf 2004, 27:991-1000.
65. Morrato E.H., Libby A.M., Orton H.D., et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008, 165(1):42-50.
66. Gibbons R.D., Brown C.H., Hur K., et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007, 164(9):1356-1363.
67. Pelkonen M., Marttunen M. Child and adolescent suicide: epidemiology, risk factors, and approaches to prevention. Paediatr Drugs 2003, 5:243-265.
68. Hatcher-Kay C., King C.A. Depression and suicide. Pediatr Rev 2003, 24:363-371.
69. Suicide Trends among Youth and Young Adults Aged 10-24 years- United States 1990-2004. MMWR Weekly 2007, 56(35):905-908. Available at:, Acceseed October 10, 2010. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5635a2.htm.
70. Oxford handbook of emergency medicine. 3rd edition. p. 609.
71. Greenhill L.L., Waslick B. Management of suicidal behavior in children and adolescents. Psychiatr Clin North Am 1997, 20:641-666.
72. Kruesi M.J., Grossman J., Pennington J.M., et al. Suicide and violence prevention: parent education in the emergency department. J Am Acad Child Adolesc Psychiatry 1999, 38:250-255.
73. Biederman J., Mick E., Spencer T.J., et al. Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. J Child Adolesc Psychopharmacol 2000, 10:185-192.
74. Belpaire H.A. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002, 3:13-37.
75. Emslie G.J., Findling R.L., Yeung P.P., et al. Venlafaxine ER for the treatment of pediatric subjects with depression: results from two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2007, 46(4):479-488.
76. Daviss W.B., Bentivoglio P., Racusin R., et al. Bupropion sustained release in adolescent with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 2001, 40(X):307-314.
77. Tao R., Emslie G., Mayes T., et al. Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorders. J Am Acad Child Adolesc Psychiatry 2009, 48(1):71-78.
78. Heiligenstein J.H., Hoog S.L., Wagner K.D., et al. Fluoxetine 40-60mg versus fluoxetine 20mg in the treatment of children and adolescents with a less than complete response to nine-week treatment with fluoxetine 10-20mg: a pilot study. J Child Adolesc Psychopharmacol 2006, 16(1-2):207-217.
79. Emslie G.J., Kennard B.D., Mayes T.L., et al. Fluoxetine verses placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 2008, 165(4):459-467.
80. Cheung A., Kusumakar V., Kutchner S., et al. Maintenance study for adolescent depression. J Child Adolesc Psychopharmacol 2008, 18(4):389-394.
81. Buckley P.F., Correll C.U. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008, 69(Suppl 1):4-17.
82. *D report. Am J Psychiatry 2007, 164(5):739-752.
83. Pathak S., Johns E.S., Kowatch R.A. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J Child Adolesc Psychopharmacol 2005, 15(4):696-702.
84. Carvalho A.F., Machado J.R., Cavalcante J.L. Augmentation strategies for treatment-resistant depression. Curr Opin Psychiatry 2009, 22(1):7-12.